Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein…
Findings indicate favorable tolerability profile and favorable pharmacokinetic and pharmacodynamic effects in patients with SCD following a single dose of…
The majority of patients experienced spleen volume and Total Symptom Score reductions Improvements were observed in anemia, bone marrow fibrosis…
99.5% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with a…
89% of evaluable patients (17/19) with transfusion-dependent β-thalassemia who do not have a β0/β0 genotype achieved transfusion independence with 11.9…
Lonca demonstrated an overall response rate of 48.3% and complete response rate of 24.1% in the pivotal Phase 2 single-agent…
Lonca demonstrated an overall response rate of 48.3% and complete response rate of 24.1% in the pivotal Phase 2 single-agent…
This publication, released during the world’s leading diabetes congress, provides unequivocal scientific endorsement of results. TOTUM-63, a plant-based active substance,…
This publication, released during the world’s leading diabetes congress, provides unequivocal scientific endorsement of results. TOTUM-63, a plant-based active substance,…
ATLANTA–(BUSINESS WIRE)–The Biotechnology Innovation Organization (BIO) released new data on the bioscience industry in the United States this week during…